Literature DB >> 20713699

Stabilization of neurotoxic Alzheimer amyloid-beta oligomers by protein engineering.

Anders Sandberg1, Leila M Luheshi, Sofia Söllvander, Teresa Pereira de Barros, Bertil Macao, Tuomas P J Knowles, Henrik Biverstål, Christofer Lendel, Frida Ekholm-Petterson, Anatoly Dubnovitsky, Lars Lannfelt, Christopher M Dobson, Torleif Härd.   

Abstract

Soluble oligomeric aggregates of the amyloid-beta peptide (Abeta) have been implicated in the pathogenesis of Alzheimer's disease (AD). Although the conformation adopted by Abeta within these aggregates is not known, a beta-hairpin conformation is known to be accessible to monomeric Abeta. Here we show that this beta-hairpin is a building block of toxic Abeta oligomers by engineering a double-cysteine mutant (called Abetacc) in which the beta-hairpin is stabilized by an intramolecular disulfide bond. Abeta(40)cc and Abeta(42)cc both spontaneously form stable oligomeric species with distinct molecular weights and secondary-structure content, but both are unable to convert into amyloid fibrils. Biochemical and biophysical experiments and assays with conformation-specific antibodies used to detect Abeta aggregates in vivo indicate that the wild-type oligomer structure is preserved and stabilized in Abetacc oligomers. Stable oligomers are expected to become highly toxic and, accordingly, we find that beta-sheet-containing Abeta(42)cc oligomers or protofibrillar species formed by these oligomers are 50 times more potent inducers of neuronal apoptosis than amyloid fibrils or samples of monomeric wild-type Abeta(42), in which toxic aggregates are only transiently formed. The possibility of obtaining completely stable and physiologically relevant neurotoxic Abeta oligomer preparations will facilitate studies of their structure and role in the pathogenesis of AD. For example, here we show how kinetic partitioning into different aggregation pathways can explain why Abeta(42) is more toxic than the shorter Abeta(40), and why certain inherited mutations are linked to protofibril formation and early-onset AD.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20713699      PMCID: PMC2932621          DOI: 10.1073/pnas.1001740107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  32 in total

1.  Comparing the folding free-energy landscapes of Abeta42 variants with different aggregation properties.

Authors:  Simon Mitternacht; Iskra Staneva; Torleif Härd; Anders Irbäck
Journal:  Proteins       Date:  2010-09

2.  Structural characterization of a soluble amyloid beta-peptide oligomer.

Authors:  Liping Yu; Rohinton Edalji; John E Harlan; Thomas F Holzman; Ana Pereda Lopez; Boris Labkovsky; Heinz Hillen; Stefan Barghorn; Ulrich Ebert; Paul L Richardson; Laura Miesbauer; Larry Solomon; Diane Bartley; Karl Walter; Robert W Johnson; Philip J Hajduk; Edward T Olejniczak
Journal:  Biochemistry       Date:  2009-03-10       Impact factor: 3.162

3.  An analytical solution to the kinetics of breakable filament assembly.

Authors:  Tuomas P J Knowles; Christopher A Waudby; Glyn L Devlin; Samuel I A Cohen; Adriano Aguzzi; Michele Vendruscolo; Eugene M Terentjev; Mark E Welland; Christopher M Dobson
Journal:  Science       Date:  2009-12-11       Impact factor: 47.728

Review 4.  Amyloid beta-protein assembly and Alzheimer disease.

Authors:  Robin Roychaudhuri; Mingfeng Yang; Minako M Hoshi; David B Teplow
Journal:  J Biol Chem       Date:  2008-10-09       Impact factor: 5.157

Review 5.  Structure-activity relationship of amyloid fibrils.

Authors:  Samir K Maji; Lei Wang; Jason Greenwald; Roland Riek
Journal:  FEBS Lett       Date:  2009-07-14       Impact factor: 4.124

6.  Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease.

Authors:  Summer L Bernstein; Nicholas F Dupuis; Noel D Lazo; Thomas Wyttenbach; Margaret M Condron; Gal Bitan; David B Teplow; Joan-Emma Shea; Brandon T Ruotolo; Carol V Robinson; Michael T Bowers
Journal:  Nat Chem       Date:  2009-07       Impact factor: 24.427

7.  Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.

Authors:  Ganesh M Shankar; Shaomin Li; Tapan H Mehta; Amaya Garcia-Munoz; Nina E Shepardson; Imelda Smith; Francesca M Brett; Michael A Farrell; Michael J Rowan; Cynthia A Lemere; Ciaran M Regan; Dominic M Walsh; Bernardo L Sabatini; Dennis J Selkoe
Journal:  Nat Med       Date:  2008-06-22       Impact factor: 53.440

8.  Abeta-globulomers are formed independently of the fibril pathway.

Authors:  Gerald P Gellermann; Helga Byrnes; Andreas Striebinger; Kathrin Ullrich; Reinhold Mueller; Heinz Hillen; Stefan Barghorn
Journal:  Neurobiol Dis       Date:  2008-02-15       Impact factor: 5.996

9.  Antiparallel beta-sheet: a signature structure of the oligomeric amyloid beta-peptide.

Authors:  Emilie Cerf; Rabia Sarroukh; Shiori Tamamizu-Kato; Leonid Breydo; Sylvie Derclaye; Yves F Dufrêne; Vasanthy Narayanaswami; Erik Goormaghtigh; Jean-Marie Ruysschaert; Vincent Raussens
Journal:  Biochem J       Date:  2009-07-15       Impact factor: 3.857

10.  Recombinant amyloid beta-peptide production by coexpression with an affibody ligand.

Authors:  Bertil Macao; Wolfgang Hoyer; Anders Sandberg; Ann-Christin Brorsson; Christopher M Dobson; Torleif Härd
Journal:  BMC Biotechnol       Date:  2008-10-30       Impact factor: 2.563

View more
  122 in total

1.  Probing amyloid fibril growth by two-dimensional near-ultraviolet spectroscopy.

Authors:  Jun Jiang; Shaul Mukamel
Journal:  J Phys Chem B       Date:  2011-04-25       Impact factor: 2.991

2.  Toxic fibrillar oligomers of amyloid-β have cross-β structure.

Authors:  James C Stroud; Cong Liu; Poh K Teng; David Eisenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

3.  High-resolution structure of a BRICHOS domain and its implications for anti-amyloid chaperone activity on lung surfactant protein C.

Authors:  Hanna Willander; Glareh Askarieh; Michael Landreh; Per Westermark; Kerstin Nordling; Henrik Keränen; Erik Hermansson; Aaron Hamvas; Lawrence M Nogee; Tomas Bergman; Alejandra Saenz; Cristina Casals; Johan Åqvistg; Hans Jörnvall; Helena Berglund; Jenny Presto; Stefan D Knight; Jan Johansson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-02       Impact factor: 11.205

4.  Molecular engineering of a secreted, highly homogeneous, and neurotoxic aβ dimer.

Authors:  Andreas Müller-Schiffmann; Aksana Andreyeva; Anselm H C Horn; Kurt Gottmann; Carsten Korth; Heinrich Sticht
Journal:  ACS Chem Neurosci       Date:  2011-03-11       Impact factor: 4.418

Review 5.  The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes.

Authors:  Iryna Benilova; Eric Karran; Bart De Strooper
Journal:  Nat Neurosci       Date:  2012-01-29       Impact factor: 24.884

6.  Identification of fibril-like tertiary contacts in soluble monomeric α-synuclein.

Authors:  Santiago Esteban-Martín; Jordi Silvestre-Ryan; Carlos W Bertoncini; Xavier Salvatella
Journal:  Biophys J       Date:  2013-09-03       Impact factor: 4.033

7.  Out-of-Register Parallel β-Sheets and Antiparallel β-Sheets Coexist in 150-kDa Oligomers Formed by Amyloid-β(1-42).

Authors:  Yuan Gao; Cong Guo; Jens O Watzlawik; Peter S Randolph; Elizabeth J Lee; Danting Huang; Scott M Stagg; Huan-Xiang Zhou; Terrone L Rosenberry; Anant K Paravastu
Journal:  J Mol Biol       Date:  2020-05-26       Impact factor: 5.469

8.  Controlling the Oligomerization State of Aβ-Derived Peptides with Light.

Authors:  Patrick J Salveson; Sepehr Haerianardakani; Alexander Thuy-Boun; Adam G Kreutzer; James S Nowick
Journal:  J Am Chem Soc       Date:  2018-04-20       Impact factor: 15.419

9.  An Efficient Method for the Expression and Purification of Aβ(M1-42).

Authors:  Stan Yoo; Sheng Zhang; Adam G Kreutzer; James S Nowick
Journal:  Biochemistry       Date:  2018-05-24       Impact factor: 3.162

Review 10.  The role of amyloidogenic protein oligomerization in neurodegenerative disease.

Authors:  Gregor P Lotz; Justin Legleiter
Journal:  J Mol Med (Berl)       Date:  2013-03-27       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.